Imaging of the heart by MRI and PET.

This review article describes the clinical usefulness and future potential of two new methods for the imaging of the heart, which have recently also become available outside research laboratories. These methods are magnetic resonance imaging (MRI) and positron emission tomography (PET). MRI is the most rapidly increasing imaging modality in medicine today. The moving heart forms a challenge to conventionally rather slow MRI-techniques. Techniques based on ECG-gating have been mandatory in making cardiac cine-MRI possible. Even though MRI provides accurate and quantitative information of the heart, conventional methods are time-consuming, confined to special laboratories, and rather expensive. Therefore, the clinical use of cardiac MRI is, in many laboratories, limited to cases in which echocardiography does not provide adequate information (e.g. pulmonary circulation) or when the patient is not willing to have transoesophageal echocardiography for better visibility. MRI is also used instead of or to complement invasive angiography to study large vessels, and it provides excellent information on paracardiac masses. Cardiac MRI is developing rapidly and within the next few years it is likely to have a profound impact on cardiac imaging. This is based on its noninvasive nature and on the comprehensive anatomic (including coronary arteries), functional, flow, perfusion and possibly also metabolic information it has the potential to provide in a manner not comparable to any other imaging method. PET is a nuclear medicine imaging modality that allows quantitative characterization of a variety of physiological and metabolic processes in vivo. Using positron-emitting flow tracers and analogues of metabolic substrates, regional myocardial blood flow, glucose and fatty acid metabolism and oxygen consumption can be studied noninvasively by PET in research as well as in clinical practice. For example, regional myocardial glucose utilization rates can be measured accurately by PET. This allows us to study the effects of nutritional interventions, hormonal and neural effects as well as disease processes on the glucose utilization of the human heart. PET is currently the only technique that permits noninvasive quantification of regional myocardial perfusion in absolute terms. Over the last decade, PET has also emerged as a clinically useful tool to study coronary artery disease and myocardial viability.

[1]  O Muzik,et al.  Assessment of myocardial perfusion by positron emission tomography. , 1991, The American journal of cardiology.

[2]  Y. Yonekura,et al.  Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. , 1989, The American journal of cardiology.

[3]  V. Dilsizian,et al.  Thallium 201 for assessment of myocardial viability. , 1991, Seminars in nuclear medicine.

[4]  K. Gould,et al.  PET perfusion imaging and nuclear cardiology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Phelps,et al.  Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  C. Higgins,et al.  Assessment of left ventricular diastolic function in dilated cardiomyopathy with cine magnetic resonance imaging: effect of an angiotensin converting enzyme inhibitor, benazepril. , 1993, American heart journal.

[7]  E Wolfe,et al.  Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. , 1990, Circulation.

[8]  C. Higgins,et al.  Magnetic resonance imaging and spectroscopy of the human heart. , 1993, Scandinavian journal of clinical and laboratory investigation.

[9]  Robert R. Edelman,et al.  Fat‐Suppressed Breath‐Hold Magnetic Resonance Coronary Angiography , 1993, Circulation.

[10]  M. Schwaiger,et al.  The clinical role of metabolic imaging of the heart by positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M Schwaiger,et al.  Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. , 1986, The New England journal of medicine.

[12]  U. Ruotsalainen,et al.  Different alterations in the insulin-stimulated glucose uptake in the athlete's heart and skeletal muscle. , 1994, The Journal of clinical investigation.

[13]  Y. Yonekura,et al.  Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  S. Rahimtoola,et al.  The hibernating myocardium. , 1989, American heart journal.

[15]  I. Kronzon,et al.  The Contribution of Magnetic Resonance Imaging to the Evaluation of Intracardiac Tumors Diagnosed by Echocardiography , 1988, Circulation.

[16]  J. Heo,et al.  The clinical relevance of myocardial viability in patient management. , 1992, American heart journal.

[17]  R Härkönen,et al.  Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. , 1994, American heart journal.

[18]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[19]  C. Higgins,et al.  Magnetic resonance imaging of cardiac and paracardiac masses. , 1989, Journal of thoracic imaging.

[20]  R. Gibbons,et al.  Position statement: clinical use of cardiac positron emission tomography. Position paper of the Cardiovascular Council of the Society of Nuclear Medicine. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  C. Hardy,et al.  Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. , 1990, The New England journal of medicine.

[22]  C. Higgins,et al.  MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction. , 1993, AJR. American journal of roentgenology.

[23]  U. Ruotsalainen,et al.  Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Schwaiger,et al.  Metabolic imaging with positron‐emission tomography , 1990, Current opinion in cardiology.

[25]  K. Yu,et al.  Delineation of acute myocardial infarction with dysprosium DTPA-BMA: influence of dose of magnetic susceptibility contrast medium. , 1992, Journal of the American College of Cardiology.

[26]  C. Higgins,et al.  Aortic dissection: sensitivity and specificity of MR imaging. , 1988, Radiology.

[27]  A. Roos,et al.  Magnetic resonance measurement of velocity and flow: technique, validation, and cardiovascular applications. , 1993, American heart journal.

[28]  D. Berman,et al.  Preoperative prediction of reversible myocardial asynergy by postexercise radionuclide ventriculography. , 1982, The New England journal of medicine.

[29]  M E Phelps,et al.  Identification and Differentiation of Resting Myocardial Ischemia and Infarction in Man with Positron Computed Tomography, 18F‐labeled Fluorodeoxyglucose and N‐13 Ammonia , 1983, Circulation.

[30]  C. Higgins,et al.  Severity of aortic regurgitation: interstudy reproducibility of measurements with velocity-encoded cine MR imaging. , 1992, Radiology.

[31]  M. Phelps,et al.  Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[32]  D N Firmin,et al.  Valve and great vessel stenosis: assessment with MR jet velocity mapping. , 1991, Radiology.

[33]  P Mansfield,et al.  Real-time echo-planar imaging by NMR. , 1984, British medical bulletin.

[34]  F G Shellock,et al.  MR imaging and biomedical implants, materials, and devices: an updated review. , 1991, Radiology.

[35]  P. Merlet,et al.  Quantification of myocardial muscarinic receptors with PET in humans. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  U. Ruotsalainen,et al.  Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  U. Ruotsalainen,et al.  Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  C. Higgins,et al.  Quantification of mitral regurgitation by velocity-encoded cine nuclear magnetic resonance imaging. , 1994, Journal of the American College of Cardiology.

[39]  E Tomei,et al.  Normal left ventricular dimensions and function: interstudy reproducibility of measurements with cine MR imaging. , 1990, Radiology.

[40]  G. Hutchins,et al.  Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. , 1991, Journal of the American College of Cardiology.

[41]  C. Higgins,et al.  Evaluation of pulmonary blood supply by nuclear magnetic resonance imaging in patients with pulmonary atresia. , 1988, Journal of the American College of Cardiology.

[42]  A. Bol,et al.  Regional Oxidative Metabolism in Patients After Recovery From Reperfused Anterior Myocardial Infarction: Relation to Regional Blood Flow and Glucose Uptake , 1992, Circulation.

[43]  H. Herzog,et al.  Kinetics of 14(R,S)-fluorine-18-fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  A. Lammertsma,et al.  Preoperative Prediction of the Outcome of Coronary Revascularization Using Positron Emission Tomography , 1992, Circulation.

[45]  D. Berman,et al.  Cardiac positron emission tomography. A report for health professionals from the Committee on Advanced Cardiac Imaging and Technology of the Council on Clinical Cardiology, American Heart Association. , 1991, Circulation.

[46]  H. Schelbert,et al.  Insights Into Coronary Artery Disease Gained From Metabolic Imaging , 1988, Circulation.

[47]  H. Iida,et al.  Myocardial tissue fraction--correction for partial volume effects and measure of tissue viability. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  S. Nelson,et al.  Evaluation of left ventricular volume and mass with breath-hold cine MR imaging. , 1993, Radiology.

[49]  M J Bronskill,et al.  Magnetic resonance imaging of the prostate. , 1985, Radiology.

[50]  C. Dence,et al.  In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. , 1990, Journal of the American College of Cardiology.

[51]  U Ruotsalainen,et al.  Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. , 1992, The Journal of clinical investigation.

[52]  U. Ruotsalainen,et al.  Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. , 1994, The American journal of physiology.

[53]  E. Hoffman,et al.  Application of annihilation coincidence detection to transaxial reconstruction tomography. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  R R Edelman,et al.  Contrast-enhanced echo-planar MR imaging of myocardial perfusion: preliminary study in humans. , 1994, Radiology.

[55]  C. Thomsen,et al.  Evaluation of left ventricular volumes measured by magnetic resonance imaging. , 1986, European heart journal.

[56]  J. Viikari,et al.  Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetes. , 1993, The American journal of physiology.

[57]  Estimating patient dielectric losses in NMR imagers. , 1984, Magnetic resonance imaging.

[58]  U. Ruotsalainen,et al.  The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  M. Schwaiger,et al.  Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. , 1992, Journal of the American College of Cardiology.

[60]  O Henriksen,et al.  Mitral and aortic valvular flow: Quantification with MR phase mapping , 1992, Journal of magnetic resonance imaging : JMRI.

[61]  N Fujita,et al.  Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve. , 1993, American heart journal.

[62]  C. Higgins,et al.  Effect of magnetic susceptibility contrast medium on myocardial signal intensity with fast gradient-recalled echo and spin-echo MR imaging: initial experience in humans. , 1994, Radiology.

[63]  P. Rigo,et al.  Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. , 1990, Journal of the American College of Cardiology.

[64]  B. Brundage,et al.  Improved regional ventricular function after successful surgical revascularization. , 1984, Journal of the American College of Cardiology.

[65]  P. Nuutila,et al.  The effect of insulin and FFA on myocardial glucose uptake. , 1995, Journal of molecular and cellular cardiology.

[66]  R. Gropler,et al.  Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. , 1992, Journal of the American College of Cardiology.